STOCKHOLM--(BUSINESS WIRE)--Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the FDA has granted clearance to proceed with VLX1570 to clinical phase I/II for treatment against relapsed and/or refractory multiple myeloma. Researchers at Vivolux have discovered a novel cancer drug target within the proteasome in tumor cells. This novel drug candidate inhibits tumor growth and prolongs survival in multiple myeloma in preclinical models that are resistant to conventional therapies.
The clinical study will be conducted in collaboration with the Memorial Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institute at Harvard Medical School. This first study is designed to determine the safety and efficacy of VLX1570 in patients with multiple myeloma who are no longer benefiting from conventional cancer treatment.
Help employers find you! Check out all the jobs and post your resume.
